EMA news on PRIority Medicines (PRIME) scheme
EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines that address patients’ unmet medical needs. The time to marketing authorisation was reduced for medicines that benefitted from PRIME support, giving patients earlier access to transformative treatments that can make a real difference to their health.
For more information: https://www.ema.europa.eu/en/news/prime-enables-earlier-availability-life-changing-medicines
OpenEdition vous propose de citer ce billet de la manière suivante :
egennet (16 mai 2022). EMA news on PRIority Medicines (PRIME) scheme. ELSIBI. Consulté le 15 mars 2026 à l’adresse https://doi.org/10.58079/o5y2





